A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 04 Feb 2019
At a glance
- Drugs MEDI-6570 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors MedImmune
- 18 Oct 2018 Planned End Date changed from 11 Jul 2019 to 13 Nov 2019.
- 18 Oct 2018 Planned primary completion date changed from 11 Jul 2019 to 21 Dec 2018.
- 18 Oct 2018 Status changed from not yet recruiting to recruiting.